Alembic Pharmaceuticals has informed that the Company has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out by them at its New Injectable Facility (F-3) at Karakhadi during the period from 28th January, 2021 to 6th February, 2021, indicating that the USFDA finds its responses to their observations to be adequate. USFDA has also indicated that a compliance verification would be performed during re-inspection of the said Facility in the next review cycle.
The above information is a part of company’s filings submitted to BSE.
